IPO registrations (S-1, F-1) · Registrants
IMMUNE PHARMACEUTICALS INC
- SEC CIK
- 1208261 · filings on EDGAR ↗
- Former names
- EPICEPT CORP (2002–2013)
- Registration
- Form S-1, first filed 2005-01-10, last 2019-01-17; 8 initial registrations, 21 amendments
- Outcome
- Final prospectus filed 2017-10-20; declared effective 2007-01-31; withdrawal requested 2005-05-19
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1 BRIDGE PLAZA N, SUITE 270, Fort Lee, NJ 07024
- EIN
- 52-1841431
- EDGAR entity type
- operating
- Insiders and CEO pay
- IMMUNE PHARMACEUTICALS INC on the corporate pages
On this site
- Form 5500 plan sponsor: IMMUNE PHARMACEUTICALS INC (BANKRUPT) EXACT (EIN (EXACT))
- Form D issuer: IMMUNE PHARMACEUTICALS INC EXACT (CIK (EXACT))
- SEC filer: EPICEPT CORP EXACT (CIK (EXACT))
Filings 55
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2005-01-10 | S-1 | S-1 (registration) | EPICEPT CORP | 0000950123-05-000197 ↗ |
| 2005-01-11 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-000242 ↗ |
| 2005-03-30 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-003736 ↗ |
| 2005-04-18 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-004613 ↗ |
| 2005-04-28 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-005193 ↗ |
| 2005-05-02 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-005402 ↗ |
| 2005-05-03 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-005484 ↗ |
| 2005-05-06 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-005726 ↗ |
| 2005-05-09 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-05-005880 ↗ |
| 2005-05-19 | RW | RW (withdrawal request) | EPICEPT CORP | 0000950123-05-006539 ↗ |
| 2006-11-30 | S-1 | S-1 (registration) | EPICEPT CORP | 0000950123-06-014716 ↗ |
| 2007-01-25 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-07-000784 ↗ |
| 2007-01-30 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-07-001051 ↗ |
| 2007-01-31 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-000381 ↗ |
| 2007-02-06 | S-1 | S-1 (registration) | EPICEPT CORP | 0000950123-07-001325 ↗ |
| 2007-04-30 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-07-006317 ↗ |
| 2007-05-29 | S-1/A | S-1/A (amendment) | EPICEPT CORP | 0000950123-07-007995 ↗ |
| 2007-06-06 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-002257 ↗ |
| 2007-06-06 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-002261 ↗ |
| 2007-06-06 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-002263 ↗ |
| 2007-07-12 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-002776 ↗ |
| 2007-08-10 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-003268 ↗ |
| 2007-09-18 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-003710 ↗ |
| 2007-12-12 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-07-004883 ↗ |
| 2008-09-11 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-08-002790 ↗ |
| 2008-10-21 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-08-003182 ↗ |
| 2008-12-19 | S-1 | S-1 (registration) | EPICEPT CORP | 0000893220-08-003223 ↗ |
| 2009-02-04 | RW | RW (withdrawal request) | EPICEPT CORP | 0000909518-09-000074 ↗ |
| 2009-07-23 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-09-002030 ↗ |
| 2011-09-08 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-11-002662 ↗ |
| 2012-04-26 | RW | RW (withdrawal request) | EPICEPT CORP | 0001104659-12-029082 ↗ |
| 2012-05-02 | EFFECT | EFFECT (declared effective) | EPICEPT CORP | 9999999995-12-001382 ↗ |
| 2014-04-14 | S-1 | S-1 (registration) | IMMUNE PHARMACEUTICALS INC | 0001437749-14-006594 ↗ |
| 2014-04-23 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001437749-14-007014 ↗ |
| 2014-04-25 | EFFECT | EFFECT (declared effective) | IMMUNE PHARMACEUTICALS INC | 9999999995-14-001138 ↗ |
| 2014-10-28 | EFFECT | EFFECT (declared effective) | IMMUNE PHARMACEUTICALS INC | 9999999995-14-003156 ↗ |
| 2014-10-28 | EFFECT | EFFECT (declared effective) | IMMUNE PHARMACEUTICALS INC | 9999999995-14-003157 ↗ |
| 2015-09-25 | EFFECT | EFFECT (declared effective) | IMMUNE PHARMACEUTICALS INC | 9999999995-15-002587 ↗ |
| 2017-01-31 | RW | RW (withdrawal request) | IMMUNE PHARMACEUTICALS INC | 0001144204-17-005049 ↗ |
| 2017-06-30 | S-1 | S-1 (registration) | IMMUNE PHARMACEUTICALS INC | 0001144204-17-035214 ↗ |
| 2017-07-18 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001144204-17-037174 ↗ |
| 2017-07-28 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001144204-17-039069 ↗ |
| 2017-08-01 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001144204-17-039552 ↗ |
| 2017-08-03 | EFFECT | EFFECT (declared effective) | IMMUNE PHARMACEUTICALS INC | 9999999995-17-002032 ↗ |
| 2017-09-11 | S-1 | S-1 (registration) | IMMUNE PHARMACEUTICALS INC | 0001571049-17-007821 ↗ |
| 2017-10-11 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001571049-17-008207 ↗ |
| 2017-10-16 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001571049-17-008247 ↗ |
| 2017-10-18 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001571049-17-008261 ↗ |
| 2017-10-18 | EFFECT | EFFECT (declared effective) | IMMUNE PHARMACEUTICALS INC | 9999999995-17-002712 ↗ |
| 2017-10-19 | S-1MEF | S-1MEF (added securities) | IMMUNE PHARMACEUTICALS INC | 0001144204-17-053118 ↗ |
| 2017-10-20 | 424B4 | 424B4 (final prospectus) | IMMUNE PHARMACEUTICALS INC | 0001571049-17-008285 ↗ |
| 2018-11-21 | S-1 | S-1 (registration) | IMMUNE PHARMACEUTICALS INC | 0001144204-18-061227 ↗ |
| 2018-12-19 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001144204-18-065450 ↗ |
| 2019-01-17 | S-1/A | S-1/A (amendment) | IMMUNE PHARMACEUTICALS INC | 0001144204-19-001967 ↗ |
| 2019-02-07 | 424B4 | 424B4 (final prospectus) | IMMUNE PHARMACEUTICALS INC | 0001144204-19-005598 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bedard John F | Director | 7 | 2006–2008 | ||
| BHAGWAT DILEEP | Officer | (see remarks); Senior VP - Pharma. Devel.; Snr VP, Pharmaceutical Dvlpmt; SVP-Pharmaceutical Development; SVP - Pharmaceutical Devlpmt | 13 | 2006–2011 | |
| Caspritz Gert | Director; Director,TenPercentOwner | 5 | 2006–2008 | ||
| Cook Robert W. | Director,Officer; Officer | CFO and Senior VP; CFO, Interim President & CEO; CFO, Snr VP, Finance & Admin; CFO - SVP - Finance & Admin; CFO-SVP, Finance & Admin.; CFO-SVP- Finance & Admin.; Interim Chief Exec. Officer | 16 | 2006–2014 | |
| Elefant Dov | Officer | Controller - VP - Fin & Admin; Controller- VP Finance & Admin | 2 | 2006 | |
| Jackson Guy C. | Director | 9 | 2006–2010 | ||
| Lockhart Earle | Officer | VP - Clinical & Reg Affairs; VP Clinical & Rglatory Affairs | 2 | 2006 | |
| McClurg Michael | Officer | VP - Bus Dvlpmnt - Oncology; VP- Business Dvpmt- Oncology | 2 | 2006 | |
| Merlin Biosciences Fund GbR | TenPercentOwnerOther | 1 | 2006 | ||
| Merlin Biosciences Fund L.P. | TenPercentOwnerOther | 1 | 2006 | ||
| Merlin General Partner II LTD | TenPercentOwnerOther | 1 | 2006 | ||
| Private Equity Direct Finance | TenPercentOwner | 1 | 2006 | ||
| Savage Robert G. | Director | 15 | 2006–2013 | ||
| Talley John V | Director,Officer | President and CEO; President, CEO and Director; President, CEO & Director | 13 | 2006–2011 | |
| Waldheim Gerhard | Director | 10 | 2006–2012 | ||
| Wiedemann Oliver | Officer | Managing Director, Med Affairs; Managing Director-Med Affairs; Managing Director-See Remarks; (see remarks); see remarks | 6 | 2006–2011 | |
| Yetter Wayne P. | Director | 10 | 2006–2012 | ||
| Tseng Ben | Officer | Chief Scientific Officer | 6 | 2006–2009 | |
| TVM III Limited Partnership | TenPercentOwner | 1 | 2006 | ||
| TVM IV GMBH & CO KG | TenPercentOwner | 1 | 2006 | ||
| TVM IV Management GmbH & Co. KG | TenPercentOwner | 1 | 2006 | ||
| TVM Techno Venture Management No. III Limited Partnership | TenPercentOwner | 1 | 2006 | ||
| Chen Michael | Officer | VP-Global Business Development | 5 | 2006–2009 | |
| Damask Michael C | Officer | Chief Medical Officer | 1 | 2006 | |
| ALLARD STEPHANE | Officer | Chief Medical Officer | 10 | 2007–2012 | |
| Smyth A. Collier | Director | 6 | 2009–2012 | ||
| Tyrrell Bernard R | Officer | Senior VP - Sales & Marketing; Senior VP Sales & Marketing | 3 | 2009–2010 | |
| Brownlie Keith L | Director | 5 | 2011–2013 | ||
| DUNTON ALAN W | Director | 4 | 2012–2013 | ||
| Albouy Pierre | Director | 2 | 2013 | ||
| De Kergrohen Herve | Director | 2 | 2013 | ||
| Kobrin Isaac | Director | 5 | 2013–2014 | ||
| Stancic Ana | Director | 4 | 2013–2015 | ||
| Teper Daniel Gedeon | Director,Officer; Director,Officer,TenPercentOwner | CEO; CEO and Chairman; Chairman & CEO | 21 | 2013–2016 | |
| SIDRANSKY DAVID | Director | 7 | 2013–2015 | ||
| LERER RENE | Director | 4 | 2013–2015 | ||
| Kazado Daniel | Director | 14 | 2013–2017 | ||
| Berdugo Gad | Director; Officer | CFO & SVP; EVP & CFO | 6 | 2014–2015 | |
| Durrant Cameron | Director | 7 | 2014–2017 | ||
| Maza Elliot M | Director; Director,Officer | Interim CEO | 6 | 2015–2017 | |
| AZRIA RENE PIERRE | Director | 3 | 2015 | ||
| Luchi Monica E. | Officer | EVP & CMO; See Remarks | 4 | 2015–2016 | |
| Ben-Ami Miri | Officer | See Remarks; See Remarks* | 3 | 2016 | |
| Militello John | Officer | See Remarks | 3 | 2016 | |
| Neczesny John A. | Director | 4 | 2016–2017 | ||
| Paley Jeffrey | Director | 4 | 2016–2017 | ||
| Kimball Ranch C | Director | 2 | 2017 | ||
| Fiorino Anthony S. | Director; Officer | Chief Medical Officer and COO | 5 | 2017–2020 | |
| Clark John P | Officer | See Remarks | 1 | 2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2014-04-14 | IMMUNE PHARMACEUTICALS INC | Pharmaceuticals | $11,720,475 | $11,720,475 | 42 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.